• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

No Word on Price. But Hadlima, on the Market in 27 Countries, ‘Has Experience,’ Says Samsung Bioepis Executive


Tom Newcomer, head of U.S. market access for the maker of Humira biosimilar Hadlima, deflected questions on price but touted the drug’s track record overseas.

Second of two parts

Everyone wants to know about price, Tom Newcomer acknowledged.

“We definitely recognize price is always going to be one of the central questions about a product before it comes to market,” Newcomer, head of U.S. market access for Samsung Bioepis says during a recent interview with Tony Hagen, a freelance writer and a regular contributor to Managed Healthcare Executive®. “It is something that we are routinely asked (about) in every discussion.”

But Newcomer, head of U.S. market access for Samsung Bioepis, the South Korean company that manufactures Hadlima, tells Hagen during the interview that pricing information is proprietary till Hadlima (adalimumab-bwwd) comes on the market. Newcomer said during the first segment of the interview that will Hadlima, which has been approved by the FDA in both a low- and high-concentration form, will come on the market “on or after” July 2023.

After years of having no competition, Humira, the top drug by sales revenue of all time, is expected to face a wave of biosimilars next year with as many as 11 coming on the market.

Although he deflected questions about price, Newcomer speaks to Hagen about Hadlima’s track record in other countries.

“The product is already out there in 27 different countries,” Newcomer says. “It has experience.” He says that despite the disruptions of the COVID-19 pandemic, Hadlima has never had supply shortages.

Related Videos
"Payer-Provider Collaboration Driving Biosimilar Utilization"
Biosimilar K-Cast - "Overcoming Challenges Associated with Biosimilars"
Biologics video - "The Benefit Channel" Pharmacy Benefits and Medical Benefits
Related Content
© 2024 MJH Life Sciences

All rights reserved.